Loading...
Loading...
KTRA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 8.0K |
| Gross Profit | -8.0K |
| Operating Expense | 2,077.0K |
| Operating I/L | -2,085.0K |
| Other Income/Expense | 74.0K |
| Interest Income | 0.0K |
| Pretax | -2,011.0K |
| Income Tax Expense | -0.0K |
| Net Income/Loss | -2,011.0K |
Kintara Therapeutics, Inc. is a clinical stage drug development company specializing in anti-cancer therapies. Their revenue is generated through the development and commercialization of late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for drug-resistant solid tumors, and REM-001, a photodynamic therapy for cutaneous metastatic breast cancer. The company also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China.
